Kinase targets and overall toxicity-related off-targets of kinase inhibitors are usually identified in the early stages of drug development. The kinase selectivity profiles are well documented in ...

A promising new malaria drug target has been identified in a family of proteins in a malaria-causing parasite.

Researchers from the Francis Crick Institute and the Gulbenkian Institute for Molecular Medicine (GIMM) have shown that the ...

Data represent the mean ± SE of four independent experiments. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. The ideas and opinions expressed in this Data Supplement do not ...

its successful commercial development facilitated investigation of the drug's other kinase targets, KIT and platelet-derived growth factor receptor (PDGFR), in other neoplasms, including SCLC.

However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

for zidesamtinib with initial target indication of TKI pre-treated patients with advanced ROS1-positive NSCLC by mid-year 2025; Report pivotal data for TKI pre-treated patients with advanced ALK ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

Kinases are considered effective targets for drug development, especially with the notable success of kinase inhibitors in cancer treatment. Nonetheless, their capabilities in treating ...

Their research is the first where exosomes have been applied to target TKI-resistant cancers in Singapore. The findings were published in the journal Developmental Cell. Epidermal growth factor ...